164 related articles for article (PubMed ID: 32738126)
1. c-KIT oncogene expression in PRKAR1A-mutant adrenal cortex.
Nadella K; Faucz FR; Stratakis CA
Endocr Relat Cancer; 2020 Oct; 27(10):591-599. PubMed ID: 32738126
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase A subunit expression is altered in Bloom syndrome fibroblasts and the BLM protein is increased in adrenocortical hyperplasias: inverse findings for BLM and PRKAR1A.
Heyerdahl SL; Boikos S; Horvath A; Giatzakis C; Bossis I; Stratakis CA
Horm Metab Res; 2008 Jun; 40(6):391-7. PubMed ID: 18401830
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.
Ragazzon B; Cazabat L; Rizk-Rabin M; Assie G; Groussin L; Fierrard H; Perlemoine K; Martinez A; Bertherat J
Cancer Res; 2009 Sep; 69(18):7278-84. PubMed ID: 19738044
[TBL] [Abstract][Full Text] [Related]
4. PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.
Bram Z; Louiset E; Ragazzon B; Renouf S; Wils J; Duparc C; Boutelet I; Rizk-Rabin M; Libé R; Young J; Carson D; Vantyghem MC; Szarek E; Martinez A; Stratakis CA; Bertherat J; Lefebvre H
JCI Insight; 2016 Sep; 1(15):e87958. PubMed ID: 27699247
[TBL] [Abstract][Full Text] [Related]
5. A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer.
Anselmo J; Medeiros S; Carneiro V; Greene E; Levy I; Nesterova M; Lyssikatos C; Horvath A; Carney JA; Stratakis CA
J Clin Endocrinol Metab; 2012 Feb; 97(2):351-9. PubMed ID: 22112814
[TBL] [Abstract][Full Text] [Related]
6. ARMC5 variants in PRKAR1A-mutated patients modify cortisol levels and Cushing's syndrome.
Maria AG; Tatsi C; Berthon A; Drougat L; Settas N; Hannah-Shmouni F; Bertherat J; Faucz FR; Stratakis CA
Endocr Relat Cancer; 2020 Sep; 27(9):509-517. PubMed ID: 32638579
[TBL] [Abstract][Full Text] [Related]
7. Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A.
Shi Z; Henwood MJ; Bannerman P; Batista D; Horvath A; Guttenberg M; Stratakis CA; Grimberg A
Growth Horm IGF Res; 2007 Apr; 17(2):113-21. PubMed ID: 17280861
[TBL] [Abstract][Full Text] [Related]
8. PRKAR1A mutations in primary pigmented nodular adrenocortical disease.
Cazabat L; Ragazzon B; Groussin L; Bertherat J
Pituitary; 2006; 9(3):211-9. PubMed ID: 17036196
[TBL] [Abstract][Full Text] [Related]
9. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.
Bertherat J; Groussin L; Sandrini F; Matyakhina L; Bei T; Stergiopoulos S; Papageorgiou T; Bourdeau I; Kirschner LS; Vincent-Dejean C; Perlemoine K; Gicquel C; Bertagna X; Stratakis CA
Cancer Res; 2003 Sep; 63(17):5308-19. PubMed ID: 14500362
[TBL] [Abstract][Full Text] [Related]
10. mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD).
de Joussineau C; Sahut-Barnola I; Tissier F; Dumontet T; Drelon C; Batisse-Lignier M; Tauveron I; Pointud JC; Lefrançois-Martinez AM; Stratakis CA; Bertherat J; Val P; Martinez A
Hum Mol Genet; 2014 Oct; 23(20):5418-28. PubMed ID: 24865460
[TBL] [Abstract][Full Text] [Related]
11. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor.
Bourdeau I; Lacroix A; Schürch W; Caron P; Antakly T; Stratakis CA
J Clin Endocrinol Metab; 2003 Aug; 88(8):3931-7. PubMed ID: 12915689
[TBL] [Abstract][Full Text] [Related]
12. PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors.
Berthon AS; Szarek E; Stratakis CA
Front Cell Dev Biol; 2015; 3():26. PubMed ID: 26042218
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor 2 (IGF2) expression in adrenocortical disease due to PRKAR1A mutations compared to other benign adrenal tumors.
Nadella KS; Berthon A; Almeida MQ; Levy I; Faucz FR; Stratakis CA
Endocrine; 2021 Jun; 72(3):823-834. PubMed ID: 33420948
[TBL] [Abstract][Full Text] [Related]
14. An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits.
Nesterova M; Bossis I; Wen F; Horvath A; Matyakhina L; Stratakis CA
J Clin Endocrinol Metab; 2008 Feb; 93(2):565-71. PubMed ID: 18056771
[TBL] [Abstract][Full Text] [Related]
15. Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice.
Sahut-Barnola I; de Joussineau C; Val P; Lambert-Langlais S; Damon C; Lefrançois-Martinez AM; Pointud JC; Marceau G; Sapin V; Tissier F; Ragazzon B; Bertherat J; Kirschner LS; Stratakis CA; Martinez A
PLoS Genet; 2010 Jun; 6(6):e1000980. PubMed ID: 20548949
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor and PKA regulatory subunit type 1A (PRKAR1A)-associated protein PAP7, and studies in PRKAR1A mutant cells and tissues.
Liu J; Matyakhina L; Han Z; Sandrini F; Bei T; Stratakis CA; Papadopoulos V
FASEB J; 2003 Jun; 17(9):1189-91. PubMed ID: 12692076
[TBL] [Abstract][Full Text] [Related]
17. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions.
Griffin KJ; Kirschner LS; Matyakhina L; Stergiopoulos SG; Robinson-White A; Lenherr SM; Weinberg FD; Claflin ES; Batista D; Bourdeau I; Voutetakis A; Sandrini F; Meoli EM; Bauer AJ; Cho-Chung YS; Bornstein SR; Carney JA; Stratakis CA
J Med Genet; 2004 Dec; 41(12):923-31. PubMed ID: 15591278
[TBL] [Abstract][Full Text] [Related]
18. Studies of mice with cyclic AMP-dependent protein kinase (PKA) defects reveal the critical role of PKA's catalytic subunits in anxiety.
Briassoulis G; Keil MF; Naved B; Liu S; Starost MF; Nesterova M; Gokarn N; Batistatos A; Wu TJ; Stratakis CA
Behav Brain Res; 2016 Jul; 307():1-10. PubMed ID: 26992826
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.
Groussin L; Kirschner LS; Vincent-Dejean C; Perlemoine K; Jullian E; Delemer B; Zacharieva S; Pignatelli D; Carney JA; Luton JP; Bertagna X; Stratakis CA; Bertherat J
Am J Hum Genet; 2002 Dec; 71(6):1433-42. PubMed ID: 12424709
[TBL] [Abstract][Full Text] [Related]
20. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex.
Robinson-White A; Meoli E; Stergiopoulos S; Horvath A; Boikos S; Bossis I; Stratakis CA
J Clin Endocrinol Metab; 2006 Jun; 91(6):2380-8. PubMed ID: 16569736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
